Advertisement

Search Results

Advertisement



Your search for The ,The matches 34690 pages

Showing 31851 - 31900


lung cancer
issues in oncology
issues in oncology

WCLC: Smoking Cessation Reduces Mortality in Low-Dose Computed Tomography Screening Volunteers

Smoking cessation among patients enrolled in a low-dose computed tomography screening program is associated with a three- to five-time reduction in mortality, according to research (Abstract PLEN04.07) presented at the 16th World Conference on Lung Cancer (WCLC) in Denver, Colorado. The Conference...

solid tumors
issues in oncology

Study Finds Nearly Half of Testicular Cancer Risk Is Inherited

A large European study that combined both population-based and genomic techniques to investigate the heritability of testicular germ cell tumor has found that 48.9% of all the possible factors contributing to risk for the disease are inherited. Rather than being the result of one faulty gene,...

palliative care

New Agent Targeting Epigenetic Modifications Shows Activity in Advanced Cancer

In a dose-escalation phase I study reported in The Lancet Oncology, Reid et al found that RRx-001, a representative of a new class of compounds called dinitroazetidines (sourced from the aerospace industry) that act on the tumor microenvironment, had activity in advanced cancers and a promising...

lung cancer

FDA Grants Alectinib Priority Review for ALK‑Positive Lung Cancer

Genentech announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Application (NDA) and granted Priority Review for alectinib, an oral investigational anaplastic lymphoma kinase (ALK) inhibitor, for the treatment of people with ALK-positive,...

colorectal cancer

Final Results of NO16968 Trial Show Improved Overall Survival With Adjuvant XELOX vs Bolus 5-FU/Leucovorin in Stage III Colon Cancer

As reported by Schmoll et al in the Journal of Clinical Oncology, the final results of the phase III NO16968 trial showed that adjuvant therapy with XELOX (capecitabine, oxaliplatin) improved overall survival vs fluorouracil (5-FU)/leucovorin in patients with resected stage III colon cancer....

lung cancer
supportive care

WCLC: Results From ROMANA Trials of Anamorelin in Advanced NSCLC Patients With Cachexia

Two phase III studies of anamorelin found that the medication effectively combats wasting and increases body weight and lean body mass in certain patients with lung cancer. Results (Abstract ORAL29.01) from the ROMANA 1 and ROMANA 2 phase III trials of anamorelin were presented at the 16th...

lung cancer
issues in oncology

WCLC: IASLC Issues Statement on Tobacco Control and Smoking Cessation


The International Association for the Study of Lung Cancer (IASLC) issued a new statement on Tobacco Control and Smoking Cessation on September 7 at the 16th World Conference on Lung Cancer (WCLC) in Denver, Colorado. The statement calls for higher taxes on tobacco products; comprehensive...

lung cancer

WCLC: Bevacizumab Plus Standard Chemotherapy Improves Survival in Mesothelioma

The standard of care for malignant pleural mesothelioma may be poised for change, judging by results from a study (Abstract ORAL11.01) by the French Cooperative Thoracic Intergroup. The addition of bevacizumab (Avastin) in the first-line setting to the current standard of care, pemetrexed...

issues in oncology
issues in oncology

WCLC: Impact of Time to Drug Approval on Potential Years of Life Lost

Every hour lost to the cancer drug regulatory process costs 29 life-years lost in the United States and 260 life-years worldwide, according to research (Abstract ORAL12.05) presented on September 7 at the 16th World Conference on Lung Cancer hosted by the International Association of the...

colorectal cancer

Improved Overall Survival With FOLFOXIRI/Bevacizumab vs FOLFIRI/Bevacizumab in First-Line Treatment of Metastatic Colorectal Cancer

In an updated analysis of the Italian phase III TRIBE trial reported in The Lancet Oncology, Cremolini et al found that FOLFOXIRI (fluorouracil [5-FU], leucovorin, oxaliplatin, irinotecan) plus bevacizumab (Avastin) significantly prolonged overall survival in patients with unresectable metastatic...

survivorship

Dose Equivalence Analysis Indicates Reduced Risk of Late Heart Failure With Daunorubicin vs Doxorubicin in Survivors of Childhood Cancer

In a study reported in the Journal of Clinical Oncology, Feijen et al found that daunorubicin may be associated with reduced risk of late heart failure vs doxorubicin in survivors of childhood cancer. Study Details The study included data from 15,815 survivors of childhood cancer who survived...

skin cancer

BRAF V600 Mutation Appears to Be Targetable Oncogene in Some but Not All Nonmelanoma Cancers

In a phase II histology-independent basket study reported in The New England Journal of Medicine, Hyman et al found that the BRAF V600 kinase inhibitor vemurafenib (Zelboraf) exhibited activity in some but not all nonmelanoma cancers with BRAF V600 mutations. Study Details In the study, 122...

issues in oncology

Online Database Helps Organize Clinically Important Cancer Gene Mutations

Many clinical trials use genome sequencing to learn which genetic mutations are present in a patient’s tumor cells. The question is important, because targeting the right mutations with the right drugs can stop cancer in its tracks. But it can be difficult to determine which particular...

lymphoma

Phase II Trial Shows Greater Activity With Lenalidomide/Rituximab vs Lenalidomide in Recurrent Follicular Lymphoma

In a phase II trial (Cancer and Leukemia Group B 50401/Alliance) reported in the Journal of Clinical Oncology, Leonard et al found that the addition of rituximab (Rituxan) to lenalidomide (Revlimid) produced a higher response rate and longer time to progression than lenalidomide alone in patients...

breast cancer
supportive care
survivorship
issues in oncology

Sham and Real Electroacupuncture Reduce Hot Flashes vs Gabapentin and Pill Placebo in Breast Cancer Survivors

In a study assessing placebo effects reported in the Journal of Clinical Oncology, Mao et al found that sham electroacupuncture produced a greater reduction in hot flashes than placebo pills and gabapentin, with the greatest reduction being achieved with real electroacupuncture. Study Details In...

issues in oncology
breast cancer

Stiffer Breast Tissue in Obese Women May Promote Tumor Growth

Women who are obese have a higher risk and a worse prognosis for breast cancer, but the reasons why remain unclear. A Cornell study published by Seo et al in Science Translational Medicine suggests that obesity changes the consistency of breast tissue in ways that predispose an individual to tumor...

survivorship

Survivors of Childhood Cancer Have High Risk of Recurrent Stroke

Recent evidence suggests that survivors of childhood cancer have a high risk of suffering a stroke at a surprisingly young age. A new study from the UC San Francisco Pediatric Brain Center shows that childhood cancer survivors suffering one stroke have double the risk of suffering a second stroke...

survivorship

Increased Risk of Cancers After Age 40 in Childhood Cancer Survivors

In an analysis from the Childhood Cancer Survivor Study reported in the Journal of Clinical Oncology, Turcotte et al found that survivors of childhood cancer are at increased risk of subsequent malignant neoplasms after age 40 years. Study Details The study involved data from 3,171 survivors of...

survivorship

Increased Risk of Intestinal Obstruction and Mortality in Survivors of Childhood Cancer

As reported by Madenci et al in the Journal of Clinical Oncology, an analysis from the Childhood Cancer Survivor Study showed that childhood cancer survivors are at increased risk of intestinal obstruction requiring surgery at ≥ 5 years after cancer diagnosis and poorer overall survival. Study...

supportive care
issues in oncology

FDA Approves Rolapitant for Prevention of Chemotherapy-Induced Nausea and Vomiting

The U.S. Food and Drug Administration (FDA) approved rolapitant (Varubi) to prevent delayed-phase chemotherapy-induced nausea and vomiting. Rolapitant is approved in adults in combination with other antiemetic agents that prevent nausea and vomiting associated with initial and repeat courses of...

Call for APOS 2016 Award Nominations

The American Psychosocial Oncology Society (APOS) will be celebrating 30 years of psychosocial oncology at the 13th Annual APOS Conference, to be held March 3 to 5, 2016, in San Diego. Colleagues, mentors, students, and others who have made an impact on psychosocial oncology can be nominated for an ...

issues in oncology
breast cancer
issues in oncology
issues in oncology

New 'Mutation-Tracking' Blood Test Could Predict Breast Cancer Relapse

Scientists have developed a blood test for breast cancer that may be able to identify which patients will suffer a relapse after treatment, months before tumors are visible on hospital scans. The test may uncover small numbers of residual cancer cells that have resisted therapy by detecting cancer...

cns cancers

Combination of Chemotherapy and T-Cell Immunotherapy May Provide Novel Treatment Strategy for Glioblastoma

A preclinical study has found that a combination of decitabine and T-cell immunotherapy demonstrated antitumor activity against glioblastomas in mouse models and was about 50% effective at curing the disease. The results, reported by Everson et al in Neuro-Oncology, show an innovative,...

multiple myeloma

Pooled Analysis Shows Improved Outcomes With Continuous vs Fixed-Duration Therapy in Newly Diagnosed Multiple Myeloma

In a pooled analysis of trials assessing novel agent-based continuous therapy vs fixed duration of therapy reported in the Journal of Clinical Oncology, Palumbo et al found that continuous therapy prolonged progression-free survival, progression-free survival-2 (time to second progression or...

multiple myeloma

FDA Accepts for Priority Review the Biologics License Application for Elotuzumab for the Treatment of Relapsed Multiple Myeloma

Bristol-Myers Squibb and AbbVie today announced that the U.S. Food and Drug Administration has accepted for priority review the Biologics License Application for elotuzumab, an investigational signaling lymphocyte activation molecule (SLAMF7)-directed immunostimulatory antibody, for the...

issues in oncology
issues in oncology

ASCO Releases Updated Policy Statement on Genetic and Genomic Testing for Cancer Susceptibility

The American Society of Clinical Oncology (ASCO) issued an updated policy statement on genetic and genomic testing for cancer susceptibility. Published in the Journal of Clinical Oncology, the statement reviews the ways in which new technologies are transforming the assessment and identification of ...

hepatobiliary cancer
issues in oncology

AAV2 Virus May Be Linked to Hepatocellular Carcinoma in Patients With No History of Cirrhosis or Other Risk Factors

More than a cause of a simple infection, viruses are often involved in the development of serious diseases. Such is the case with liver cancer, which often develops in an organ that has been weakened by hepatitis B or C virus. Researchers at Inserm, the Paris Public Hospitals (AP-HP), Paris...

integrative oncology
issues in oncology
issues in oncology
issues in oncology

High Use of Complementary or Alternative Medicines in Older Patients With Cancer

Alternative medicines are widely thought to be at least harmless, and very often helpful, for a wide range of discomforts and illnesses. However, although they’re marketed as “natural,” they often contain active ingredients that can react chemically and biologically with other...

Study Finds Modified CAR T Cells Can Selectively Target Solid Tumor Cells While Sparing Healthy Cells

Chimeric antigen receptor (CAR) T cells that are currently being tested to treat B-cell malignancies target a specific protein present on leukemia and lymphoma cells, but these immune cells cannot distinguish the cancer cells from healthy cells. However, the side effects from these CAR T cells...

Similar Outcomes With Tinzaparin vs Warfarin in Treatment of Acute Venous Thromboembolism in Patients With Active Cancer

In the phase III CATCH trial reported in JAMA, Lee et al found that the low–molecular-weight heparin tinzaparin (Innohep) did not significantly reduce the risk of recurrent venous thromboembolism vs warfarin in the treatment of acute symptomatic venous thromboembolism in patients with active...

Activity of Colony-Stimulating Factor-1 Receptor Kinase Inhibitor in Tenosynovial Giant Cell Tumors

In a phase I study reported in The New England Journal of Medicine, Tap et al found that a newly developed inhibitor of colony-stimulating factor-1 receptor (CSF1R) kinase showed activity in tenosynovial giant cell tumors. CSF1 gene expression is elevated in most such tumors. The structure of the...

colorectal cancer

Aspirin Reduces Obesity-Related Colorectal Cancer Risk in Patients With Lynch Syndrome

In an analysis of a randomized trial of aspirin in patients with Lynch syndrome reported in the Journal of Clinical Oncology, Movahedi et al found that obesity was associated with an increased risk of colorectal cancer, with the excess risk being restricted to those not receiving aspirin. ...

breast cancer
supportive care
survivorship
issues in oncology
issues in oncology

Fertility Concerns and Side Effects Keep Many Young Women With Breast Cancer From Taking or Completing Tamoxifen

Concerns about fertility kept one-third of young women with breast cancer surveyed in a recent study from taking tamoxifen, despite its known benefit in reducing the risk of breast cancer recurrence. In addition, the study found fertility concerns led one-quarter of women who started...

breast cancer

Pericytes May Help Some Tumors Evade the Immune System

A study by researchers at Sweden's Karolinska Institutet is reportedly the first to suggest that cells in the tumor blood vessels contribute to a local environment that protects the cancer cells from tumor-killing immune cells. The results, published by Hong et al in the Journal of the...

lymphoma
issues in oncology

Integration of Mutation Status to FLIPI Improves Risk Stratification for Patients Receiving First-Line Immunochemotherapy for Follicular Lymphoma

In a study reported in The Lancet Oncology, Pastore et al found that the addition of mutation status of seven genes to the Follicular Lymphoma International Prognostic Index (FLIPI) and Eastern Cooperative Oncology Group (ECOG) performance status produced a clinicogenetic model (m7-FLIPI) with high ...

lymphoma

Consolidative Radiotherapy Underused in Early‑Stage Diffuse Large B-Cell Lymphoma

In a study reported in the Journal of Clinical Oncology, Vargo et al found that use of consolidative radiotherapy, which continues to decline, is associated with a survival benefit compared with multiagent chemotherapy alone in patients with early-stage diffuse large B-cell lymphoma. Study Details ...

issues in oncology

Study Validates Method for Patient Reporting of Cancer Drug–Related Adverse Events

In cancer clinical trials, doctors typically report side effects that patients experience—not patients themselves. Previous research has shown that doctors underreport these symptoms. Ethan Basch, MD, MSc, Director of the UNC Lineberger Cancer Outcomes Research Program and Associate...

breast cancer
issues in oncology
issues in oncology
issues in oncology

Black Women Have Higher Frequency of BRCA Mutations Than Previously Reported

Women who have inherited mutations in the BRCA1 or BRCA2 gene are more likely to develop breast cancer or ovarian cancer, especially at a younger age. Approximately 5% of women with breast cancer in the United States have mutations in BRCA1 or BRCA2, based on estimates in non-Hispanic white women. ...

Preclinical and Clinical Evidence of Lack of Sprouting Angiogenesis in Development of Lymph Node Metastases

In preclinical and clinical studies reported in the Journal of the National Cancer Institute, Jeong et al found a lack of sprouting angiogenesis in the formation of lymph node metastases, suggesting a potential mechanism for resistance to antiangiogenic treatments in adjuvant settings. The study...

breast cancer

Report of Secondary Outcomes in NSABP B-40 Indicates Improved Overall Survival With Neoadjuvant Plus Adjuvant Bevacizumab in Early Breast Cancer

The phase III NSABP B-40 (NRG Oncology) trial showed that the addition of bevacizumab (Avastin) to docetaxel-based neoadjuvant chemotherapy improved pathologic complete response rate, the primary endpoint, in patients with early HER2-negative breast cancer. In a report of secondary outcomes in The...

colorectal cancer
issues in oncology

Longer Colonoscopies Linked to Lower Rate of Colorectal Cancer

Research by a Veterans Affairs team has confirmed that longer-lasting colonoscopies are associated with lower cancer rates. Their findings were published by Shaukat et al in Gastroenterology, and were based on nearly 77,000 screening colonoscopies. Experts already know about the link between...

gynecologic cancers

Beta-Blockers May Prolong Survival in Women With Ovarian Cancer

In a first-of-its-kind study, researchers demonstrated a benefit in overall survival among patients with epithelial ovarian cancer receiving generic beta-blocker heart medications. Survival was shown to be greatest among those prescribed first-generation nonselective beta-blockers. According to...

lung cancer

European Trial Indicates No Additional Benefit From Preoperative Radiotherapy Following Neoadjuvant Chemotherapy in Stage IIIA/N2 NSCLC

In a phase III trial reported in The Lancet, Pless et al in the Swiss Group for Clinical Cancer Research found that adding preoperative radiation following neoadjuvant chemotherapy did not appear to improve outcomes vs neoadjuvant chemotherapy alone in patients with stage IIIA/N2 non–small...

breast cancer
health-care policy
issues in oncology

Introduction of Generic Aromatase Inhibitors Reduces Decline in Adherence in Medicare D Breast Cancer Patients Without Low-Income Subsidy

Adherence to aromatase inhibitor treatment for breast cancer declines over time. In a study reported in the Journal of the National Cancer Institute, Neuner et al found that introduction of generic aromatase inhibitors resulted in a reduction in decline in adherence among patients with breast...

skin cancer
issues in oncology

Patients With Fewer Than 50 Moles May Be at Risk for More Aggressive Melanoma

People with more than 50 moles have an increased risk of developing melanoma, but those with fewer than 50 moles should still be alert for this disease. In fact, according to new research presented at the American Academy of Dermatology’s 2015 Summer Academy Meeting in New York, those with...

gynecologic cancers
issues in oncology

Imaging Probe May Be More Accurate Than the Best External Detector for Early Cervical Cancer Diagnosis

An endovaginal magnetic resonance imaging technique is more accurate at detecting early-stage cervical cancer than the best available external detection technique, a new study reported. Researchers at The Institute of Cancer Research and The Royal Marsden Hospital found that using an...

breast cancer
issues in oncology

Study Finds Many Women Experience Long-Term Psychosocial Consequences of False-Positive Screening Mammography

Although mammographic screening leads to reductions in breast cancer mortality, some women experience psychosocial side effects and do not benefit from screening, according to a study by Bolejko et al investigating the prevalence and predictors of the psychosocial consequences of false-positive...

colorectal cancer

Long-Term Use of Aspirin and Nonsteroidal Anti-inflammatory Drugs May Be Associated With Reduced Colorectal Cancer Risk

A large population-based control study of the use of low-dose aspirin or other nonsteroidal anti-inflammatory drugs and colorectal cancer risk has found that taking 75 mg to 150 mg of aspirin for 5 years or longer was associated with a 27% reduced risk of colorectal cancer. In addition, 5 or more...

issues in oncology
lymphoma

Digital Gene Expression Cell of Origin Assay Shows High Prognostic Ability in Diffuse Large B-Cell Lymphoma

In a study reported in the Journal of Clinical Oncology, Scott et al found that the digital gene expression–based Lymph2Cx assay produced concordant cell of origin assignments in formalin-fixed paraffin-embedded tissue biopsies from patients with diffuse large B-cell lymphoma and showed high...

FDA Approves Eltrombopag for Pediatric Patients With Chronic Immune Thrombocytopenia

The U.S. Food and Drug Administration approved eltrombopag (Promacta) for the treatment of thrombocytopenia in pediatric patients aged 1 year and older with chronic immune thrombocytopenia who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. The approval was...

Advertisement

Advertisement




Advertisement